 |
|
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).
Number of employees : 47 000 people.
|
|
|
| 2020 | | Immunology | 22 153.00 | 48.4% |
| Other | 8 057.00 | 17.6% |
| Hematologic Oncology | 6 651.00 | 14.5% |
| Neuroscience | 3 496.00 | 7.6% |
| Aesthetics | 2 590.00 | 5.7% |
| Eye Care | 2 184.00 | 4.8% |
| Women's Health | 673.00 | 1.5% |
| USD in Million |
|
|
|
| 2020 | | United States | 34 879.00 | 76.1% |
| All Other Countries | 3 977.00 | 8.7% |
| Japan | 1 198.00 | 2.6% |
| Canada | 1 159.00 | 2.5% |
| Germany | 1 049.00 | 2.3% |
| France | 797.00 | 1.7% |
| Australia | 527.00 | 1.2% |
| United Kingdom | 509.00 | 1.1% |
| China | 471.00 | 1% |
| Spain | 453.00 | 1% |
| Brazil | 406.00 | 0.9% |
| Italy | 379.00 | 0.8% |
| USD in Million |
|
|
|
| Vote  | Quantity | Free-Float | Company-owned shares | Total Float |
| Stock A |
1 |
1,801,854,577 |
1,765,787,339 |
98.0% |
33,974,112 |
1.9% |
98.0% |
|
|
|
| Name | Equities | % | | The Vanguard Group, Inc. | 137,856,527 |
7.80% | | SSgA Funds Management, Inc. | 76,760,629 |
4.34% | | BlackRock Fund Advisors | 37,798,586 |
2.14% | | JPMorgan Investment Management, Inc. | 31,474,672 |
1.78% | | Geode Capital Management LLC | 27,760,592 |
1.57% | | T. Rowe Price Associates, Inc. (Investment Management) | 26,208,021 |
1.48% | | Northern Trust Investments, Inc.(Investment Management) | 22,815,720 |
1.29% | | Capital Research & Management Co. (Global Investors) | 19,009,911 |
1.08% | | Fidelity Management & Research Co. LLC | 18,057,685 |
1.02% | | Morgan Stanley Smith Barney LLC (Investment Management) | 16,776,958 |
0.95% |
|
|
|
|
- Main Market - S&P 100 / S&P 500, Stoxx Americas 100, Stoxx Global 200, Stoxx NorthAmerica 50, Stoxx USA 50 |
|
|
|
|
| - Bloomberg Code : |
|
| - Reuters Code : |
ABBV.N |
| - Datastream Code : |
|
|
| Company contact information |
|
|
|
|
|
Report says drugmakers impose unjustified U.S. price increases; spending on AbbVie drug rises $1.4 billion |
Sector Other Pharmaceuticals
Connections : AbbVie Inc. |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
